Cargando…
Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670490/ https://www.ncbi.nlm.nih.gov/pubmed/23632481 http://dx.doi.org/10.1038/bjc.2013.211 |
| _version_ | 1782271857274126336 |
|---|---|
| author | Rosario, D J Bourke, L |
| author_facet | Rosario, D J Bourke, L |
| author_sort | Rosario, D J |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3670490 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36704902014-05-28 Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Rosario, D J Bourke, L Br J Cancer Letter to the Editor Nature Publishing Group 2013-05-28 2013-04-30 /pmc/articles/PMC3670490/ /pubmed/23632481 http://dx.doi.org/10.1038/bjc.2013.211 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
| spellingShingle | Letter to the Editor Rosario, D J Bourke, L Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title | Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title_full | Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title_fullStr | Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title_full_unstemmed | Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title_short | Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| title_sort | reply: endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670490/ https://www.ncbi.nlm.nih.gov/pubmed/23632481 http://dx.doi.org/10.1038/bjc.2013.211 |
| work_keys_str_mv | AT rosariodj replyendocrinetherapyinprostatecancertimeforreappraisalofrisksbenefitsandcosteffectiveness AT bourkel replyendocrinetherapyinprostatecancertimeforreappraisalofrisksbenefitsandcosteffectiveness |